Skip to main content
SpringerLink
Log in

Melanom

Adjuvante Therapie im Stadium II

  • Fortbildung
  • Published:
hautnah dermatologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. S3-Leitlinie "Diagnostik, Therapie und Nachsorge des Melanoms", AWMF-Registernummer 032-024OL

  2. Rehani MM et al. Estimates of the number of patients with high cumulative doses through recurrent CT exams in 35 OECD countries. Phys Med 2020; 76: 173-6

  3. Luke JJ et al. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase 3 trial. Ann Oncol 2021; 32 (Suppl.): 1283-346

Download references

Author information

Authors and Affiliations

  1. Klinik für Dermatologie/Allergologie, Universiätsklinikum Schleswig-Holstein - Campus Kiel -, Arnold-Heller-Str. 3, 24105, Kiel, Deutschland

    Axel Hauschild

Authors
  1. Axel Hauschild
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel Hauschild.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hauschild, A. Adjuvante Therapie im Stadium II. hautnah dermatologie 38 (Suppl 1), 16–19 (2022). https://doi.org/10.1007/s15012-021-6826-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-021-6826-2

Search

Navigation